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Abstract
Paragangliomas are rare tumors of neural crest origin. They are benign
in the majority of cases and are characterized by a strong vascularisa-
tion.
Carsten Christof
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In the head and neck region they most commonly occur as carotid body
tumors. Jugulotympanic and especially vagal paragangliomas are seen 1 Department of
Otorhinolaryngology, Head lessfrequently.Completesurgicalresectionrepresentstheonlycurative
and Neck Surgery, University
of Freiburg, Germany
treatment option even though resection of locally advanced tumors
regularlyresultsinlesionsofthelowercranialnervesandmajorvessels.
Appoximately 30% of all head and neck paragangliomas (HNPs) are
hereditary and associated with different tumor syndromes. The
paraganglioma syndromes 1, 3 and 4 (PGL 1, 3 and 4) make up the
majority of those familial cases. PGL 1 is associated with mutations of
the succinate dehydrogenase subunit D (SDHD) gene, PGL 3 is caused
by SDHC and PGL 4 by SDHB gene mutations. Multiple HNPs and the
occuranceofHNPstogetherwithpheochromocytomasareseeninSDHD
as well as SDHB mutation carriers. In patients with SDHB mutations
the risk for the development of malignant paraganglial tumors is signi-
ficantlyhighercomparedtoSDHCandSDHDpatientsaswellaspatients
withsporadictumors.SDHCmutationcarriersalmostexclusivelypresent
with benign HNP that are unifocal in the majority of cases. The role of
transmission is autosomal dominant for all three symptoms. Interest-
ingly, there is a “parent-of-origin-dependent-inheritance” in subjects
with SDHD gene mutations. This means that the disease phenotype
may only become present if the mutation is inherited through the pa-
ternalline.WerecommendscreeningformutationsofthegenesSDHB,
SDHCandSDHDinpatientswithHNPs.Certainclinicalparameterscan
help to set up the order in which the three genes should be tested.
Keywords: paraganglioma, glomus tumor, pheochromocytoma,
paraganglioma syndrome, rare diseases
1. Introduction
Head and neck paragangliomas (HNPs) represent rare
tumors of neural crest origin [1], [2]. They are highly
vascular neoplasms that are benign in the majority of
cases[1],[2],[3].Theymayoccuralongtheparaganglia's
pathway of embryologic migration extending from the
skull base to the pelvic floor [1], [2], [4], [5], [6].
Paraganglia play an importatnt role in organismic
homeostasisbyactingaschemoreceptorsorbysecretion
ofcatecholaminesinresponsetostress[4].Paraganglial
tumors in the thorax and the abdomen are referred to as
pheochromocytomas [1], [7], [8].
Terminology
Terminology in science and clinical practice regarding
tumors of the paraganglial system is divergent [9], [10],
[11]. According to the suggestions of Neumann and
coworkers we will use the term pheochromocytoma for
all tumors in the thorax and the abdomen whereas the
term head and neck paraganglioma (HNP) is only used
for tumors in the head and neck region [9]. The vast
majorityofallpheochromocytomasareendocrinologically
active. HNP on the other hand are almost exclusively
nonfunctioning [9].
The terms glomus tumor and chemodectoma are often
used for HNP [12], [13]. The term glomus tumor is
somewhatconfusingthough,sinceitmayeasilybemixed
up with a benign tumor of the subcutaneous skin, the so
called glomangioma [2], [14], [15]. The term chemodec-
tomahasfirstbeenusedbyMulliganin1950[16].Strictly
speaking it is not correct either, since regarding
paraganglia in the head and neck only the carotid body
paraganglia act as chemoreceptors [17]. The terms
glomus tumor and chemodectoma should therefore not
be used any more [17], [18].
Incidence and localisation
HNP are rare neoplasms comprising about 0.03% of all
human tumors [2], [6]. The yearly incidence is estimated
to be at around 0.001% [2].
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mas in the head and neck. The CBT represents the most
common tumor type [1], [19], [20], [21]. Other paragan-
gliomas (PGs) that are frequently detected in the head
andneckincludejugularPGs,tympanicPGsand,although
less common vagal PG [2], [22], [23]. PGs in the nose
[24], the paranasal sinuses [25], parotid gland [26], cer-
vical sympathatic chain [27], [28], larynx [29], [30], [31],
thyroid gland [32], parathyroid gland [33], esophagus
[34] or the orbit [35] are exceedingly rare.
Function of paraganglia in the head and
neck
Paraganglia in the carotid body work as chemoreceptors
measuring hypoxia, hypercapnia and ph value in arterial
blood. Via the glossopharyngeal nerve they are directly
connected to the respiratory centers in the central
nervous system. Carotid body paraganglia are involved
in regulation of respiration and blood pH value, blood
pressureandheartrate[36],[37],[38],[39].Thefunction
of the other head and neck paraganglia remains less
clear [40].
Etiology
Many etiologic aspects of HNP development remain un-
clear [36], [41]. Sporadic CBTs have been demonstrated
tobemorefrequentinpeoplelivingathighaltitudes[42]
andinpatientswithchronicobstructivelungdisease[42].
Therefore, a chronic hypoxic stimulation probably plays
an important role in the occurance of those unusual
neoplasms [36], [42], [43].
Age at diagnosis and sex distribution
HNPs may occur at any age [36], [44]. Most patients be-
come symptomatic between their 30
th and their 60
th
birthday [36], [45]. Concerning sex distribution, there is
aclearfemalepredominancebyafactorofapproximately
3:1 until 4:1 [1], [10], [17], [46], [47], [48], [49].
2. Discussion
2.1 Symptoms
CBTs often remain clinically silent before they present as
a painless, slowly enlarging mass in the lateral neck [1],
[4], [21], [36], [45], [48]. In later stages of tumor devel-
opment dysphagia, deficits of the cranial nerves VII, IX,
X, XI and XII as well as Horner's syndrome may be seen
[4], [48].
Physical examination typically reveals a rubbery, non-
tender mass in the lateral neck. The lesion is more freely
moveable in a horizontal plane than vertically, which is
referred to as a positive Fontaine's sign. The finding of a
carotid bruit or a pulsatile character of the tumor
strenthens the tentative diagnosis of a CBT. A careful
examination for deficits of the lower cranial nerves as
well as the cervical sympathetic chain is mandatory [4],
[48].
TympanicPGsusuallybecomesymptomaticasapulsatile
tinnitus that might be accompanied by a conductive
hearing loss. In patients with jugular PGs there may be
lower cranial nerve deficits in addition [2], [3], [46], [49],
[50]. Tympanic as well as jugular PGs usually present to
the otorhinolaryngologist by means of a bluish, pulsating
mass behind the ear drum [2].
Vagal PGs most commonly arise from the inferior nodose
ganglionbuttheymayoccuratanypointalongthecourse
of the cervical vagal nerve [4]. Therefore, there is a wide
variety of possible symptoms ranging from a painless
mass in the lateral neck to dysphagia, cranial nerve defi-
cits and Horner´s syndrome [17].
The rate of functioning HNPs is low. About 1-3% of HNPs
present with elevated catecholamines and subsequent
tachycardia, tremor and hypertension [18], [48], [51],
[52]. Secretion of dopamine with resulting hypotension
is very infrequently seen in HNP patients [52].
2.2 Diagnosis
2.2.1 Radiology
Aftertakingthepatient´shistoryandathoroughexamin-
ation of the head and neck region an evaluation by ima-
ging procedures is absolutely necessary to establish the
diagnosis of a HNP.
In cervical HNPs, B-mode sonography with color-coded
Doppler sonography represents an inexpensive, non-in-
vasivediagnostictoolfrequentlyusedasthefirstimaging
step [1], [2], [53], [54]. A CBT will typically present as a
solid, well-defined, hypoechoic tumor with a splaying of
thecarotidbifurcation[1],[54].Theexternalcarotidartery
(ECA)isusuallydisplacedanteriorlyandmediallywhereas
the internal carotid artery (ICA) is typically displaced
posteriorly and laterally [54], [55].
VagalPGsoftendisplaceboththeECAandtheICAanteri-
orly.Theinternaljugularveinistypicallycompressedand
displaced posteriorly [55], [56]. In large vagal PGs there
may also be a splaying of the carotid bifurcation [56].
Incolor-codedduplexsonography,cervicalHNPstypically
present as hypervascular masses. It is important to
mentionthoughthattheabsenceofhypervascularitydoes
not exclude a cervical HNP [54].
Magnetic resonance imaging (MRI) today plays the most
important role in the pretherapeutic evaluation of HNPs.
HNPstypicallyshowahyperintensesignalonT2-weighted
images and a distinct contrast enhancement on the T1-
weightedimages[57].MRIalsopresentstheexactexten-
sion of the tumor and its exact relationship to the carotid
vessels. The classification of CBTs is according to criteria
set forth by Shamblin [58]. Class I tumors are localized
tumors with splaying of the carotid bifurcation but little
attachmenttothecarotidvessels.ClassIItumorspartially
surround the carotid vessels and Shamblin class III CBTs
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Boedeker: Paragangliomas and paraganglioma syndromesFigure 1a: CBT (class I): The axial T1-weighted MRI with contrast medium shows a CBT in typical location. Splaying of the left
carotid bifurcation without any surrounding of the carotid vessels.
Figure 1b: CBT (class II): Axial T1-weighted MRI with contrast showing a right-sided CBT partially surrounding the internal and
external carotid artery.
Figure 1c: CBT (class III): A large left-sided CBT intimately surrounding the carotid vessels (axial T1 weighted MRI with contrast).
intimately surround the carotids [58]. Figure 1 demon-
strates those three classes of CBTs.
Figure 2: Dynamic contrast-enhanced magnetic resonance
angiography (MRA) of a 44 year old male SDHD mutation
carrier. Note bilateral CBTs and a jugular paraganglioma on
the right in the early arterial phase.
In jugulotympanic HNPs the MRI is helpful to detect dura
infiltration and intradural tumor growth. It is also needed
to exclude other tumor entities occuring in the area such
as neurinomas and endolymphatic sac tumors (ELST)
[59]. Today, the MRI will be performed in combination
with a dynamic contrast-enhanced magnetic resonance
angiography (MRA). The MRA helps to diagnose or rule
out additional paragangliomas in the head and neck
(Figure 2) [59].
Computed tomography (CT) is needed to evaluate jugu-
lotympanic HNPs. The extend of temporal bone destruc-
tion is important to classify those tumors according to
the Fisch classification (Table 1) [60]. This preoperative
classification is essential, since the surgeon will choose
the operative approach depending on tumor stage [59].
Digital substraction angiography (DSA) provides an arter-
ial„map“andidentifiesthebloodsupplyandflowdynam-
ics of the tumor. It also provides endovascular access for
tumorembolisation[1],[2],[3],[48],[54].Asaninvasive
imaging procedure, DSA is not free of side affects. Today,
it should only be performed when there is the need for
pre-operative tumor embilisation. In all other cases, an
MRA should be performed [59], [61].
2.2.2 Nuclear medicine
Theroleofmetabolicimagingproceduresinthediagnosis
of HNPs as well as pheochromocytomas has greatly in-
creased within the last 10 years [13], [57], [62], [63],
[64], [65].
The 123I-Metaiodobenzylguanidin-szintigraphy (MIBG
szintigraphy)hasoftenbeenusedasametabolicimaging
toolinthediagnosisofneuroendocrinetumors[62],[63],
[64].Thetracerneeded,[123I]MIBG,isreadilyavaileable
in all nuclear medicine centers in Germany. MIBG szinti-
graphy also has some clear disadvantages though. The
images are made two and 24 hours after intraveneous
application of the tracer which means that patients do
have to come in twice. The tracer also interferes with
many common drugs such as heart medication, blood
pressure medication and antidepressants. Moreover,
[123I]MIBG is often accumulated in the salivary glands
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which complicates proper diagnosis [57]. In addition,
sensitivity is not very high [57].
Figure 3:
18F-DOPA-PET presenting a right CBT, a right jugular
paraganglioma, a remnant of a left CBT as well as
pheochromocytomasintheleftatriumandinprojectiontothe
aortic arch. This 41 year old male SDHD patient had already
undergone surgery for bilateral abdominal
pheochromocytomas. Physiologic tracer uptake is seen in the
gallbladder, the renal pelvis and the urinary bladder.
At the University of Freiburg Medical Center the 18F-
Fluorodihydroxyphenylalanin positron emission tomo-
graphy (18F-DOPA-PET) has been used for more than ten
years in the diagnosis of paraganglial tumors. Hoegerle
et al. could demonstrate as early as 2002 that the 18F-
DOPA-PET is an excellent tool for the detection of pheo-
chromocytomas which is superior to MIBG szintigraphy
[13]. The following year, the same could be shown for
HNPs [57]. 18F-DOPA-PET is capable to detect even very
small paraganglial tumors and metastatic disease. The
tracer is not accumulated in the head and neck. With a
single procedure, paraganglial tumors in the head and
neck,thethoraxaswellastheabdomenmaybedetected
(Figure 3). On the downhand side, the tracer is only
available at selected nuclear medicine centers [57].
Other nuclear medicine procedures frequently used for
the diagnosis of paraganglial tumors include 18F-fluoro-
dopamin-PET (18F-FDA-PET), 18F-fluoro-2-deoxy-D-gluc-
ose-PET(18F-FDG-PET)[64]andthe68Ga-DOTA-D-Phe1-
Tyr3-octreotate-PET(68Ga-DOTATATE-PET)(Figure4)[66],
[67].
The PET examinations mentioned are often combined
withaCTscan.ThosefusionsbetweenPETandCT(Figure
5) lead to an increased specifity and sensitifity [65].
Luster et al. recently examined 25 paraganglioma and
pheochromocytoma patients with 18F-DOPA-PET/CT fu-
sions. Sensitivity in this study was 100%, specifity was
88% with a positive predictive value of 100% and a neg-
ative predictive value of 88% [65].
4/26 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2011, Vol. 10, ISSN 1865-1011
Boedeker: Paragangliomas and paraganglioma syndromesFigure 4:
68Ga-DOTATATE-PET with multiple bone metastases
in the spine, the rips and at the skull base (marked by arrows).
Physiologictraceruptakeintheliver,thekidneys,theadrenals,
the stomach, pancreas, spleen and the small bowel. This 41
year old female SDHB mutation carrier had first undergone
resection of a malignant carotid body tumor with regional
lymph node metastases seven years earlier.
Figure 5: Frontal fusion between computed tomography and
PETaffirmsthespinalmetastasisintheSDHBmutationcarrier
from Figure 4.
2.2.3 Histopathology and
immunhistochemistry:
HNPs as well as pheochromocytomas are basically com-
posedoftwocelltypes:chiefcellsandsustentacularcells
[6], [68], [69], [70], [71]. The histological aspect of the
tumor is the typical „Zellballen“ pattern where nests or
cordsofchiefcellsaresurroundedbysustentacularcells
(Figure6).Paraganglialtumorsderivefromthechiefcells
and are benign neoplasms in the majority of cases [4],
[20], [72], [73]. Overall less than 10% of HNPs are cited
to be malignant [1], [3], [6], [48]. Interestingly, there are
no histopathological or immunohistochemical criteria for
the diagnosis of a malignant paraganglial tumor. There-
fore, a malignant HNP or pheochromocytoma may only
be diagnosed when there is metastasis to non neuroen-
docrine tissue [1], [3], [4], [6], [18], [48]. In HNPs, meta-
stasesaremostfrequentlyfoundincervicallymphnodes.
Distant metastases are most common in bone, liver and
lung [44], [74], [75], [76], [77], [78], [79].
Figure 6: The hematoxiline-eosine staining reveals chief cells
in a classical “Zellballen” pattern surrounded by ectatic blood
vessels and sustentacular cells (original magnification x100).
Immunohistochemically, chief cells express neuroendo-
crinemarkerssuchasCD56,synaptophsin,chromogranin
(Figure 7), and neuron specific enolase (Figure 8) [68],
[69], [74], [80]. Sustentacular cells are positive for the
S-100 protein (Figure 9) [68], [69], [74], [81].
Whether fine needle aspiration biopsy (FNA) should be
usedasameansofconfirmingaclinicaldiagnosisofHNP
is controversial. Monatabi and coworkers report on their
results regarding FNA in 13 patients with CBT [82]. The
authorsstatethatthecorrectdiagnosisofaCBTwithFNA
is „extremely difficult“. Nevertheless they regard FNA as
an important tool for the pre-therapeutic diagnosis of
HNPs.Ontheotherhand,aspiratesfromCBTshavebeen
mistaken for many different neoplasms including neur-
ofibroma, neurofibrosarcoma, malignant melanoma, dif-
ferentformsofthyroidcanceraswellasmetastasesfrom
acarcinoma[68].Inadditiontothequestionablediagnost-
ic value of a FNA in HNPs one has to consider potential
side effects such as heavy bleeding [68].
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ative diagnosis of HNPs. It is a potentially dangerous ex-
amination with a very low sensitivity and specifity.
Figure 7: On immunhistochemistry the chief cells are positive
for chromogranin (original magnification x200).
Figure 8: Positive staining of the chief cells for NSE (original
magnification x100).
Figure 9: S-100 positive sustentacular cells surrounding the
chief cells (original magnification x100).
2.3 Differential diagnosis
Cervical HNPs often become symptomatic by means of
a painless, slowly enlarging lateral neck mass [1], [4],
[21], [36], [45], [48]. The differential diagnosis of a non-
tender lateral neck mass includes lymphadenopathies,
branchial cleft cysts, salivary gland tumors, neurogenic
tumors, aneurysms of the carotid artery as well as HNPs
[36], [45]. Differentiation between a HNP and the other
massesmentionedcanusuallyeasilybemadebymeans
of the radiologic as well as functional imaging modalities
mentioned above.
JugulotympanicHNPsoftenpresentwithpulsatiletinnitus
[2],[3],[46],[49],[50].Gehrkingetal.reviewedpossible
causes of pulse synchronous tinnitus [50]. Jahnke and
Klingbeil reported on a patient with pulsatile tinnitus
caused by an intratympanic encephalocele [83].
Schikschneit and coworkers added an amputation neur-
oma of the middle ear as another unusual cause for
pulsatile tinnitus [84].
Table 2 features possible causes for the symptom
„pulsatile tinnitus“.
Differentiation between a jugulotympanic PG and the
other causes mentioned can be obtained by a thorough
examinationoftheearincombinationwiththeradiologic
examinations above.
2.4 Therapy
The management of HNPs remains controversial [1], [3],
[4], [37], [48], [85], [86], [87]. The current treatment
options include surgical resection [1], [2], [3], [19], [48],
[59],[88],[89],conventionalradiationtherapy[47],[90],
[91], [92], stereotactic radiosurgery (for jugulotympanic
PGs only) [85], [86], [93], permanent embolisation [20],
[37] and a combination of those modalities.
DuetothefactthatHNPsareusuallyslow-growingtumors
it may be appropriate under certain circumstances to
withhold any kind of invasive therapy and to observe tu-
mor growth with serial MRI studies („wait and scan“) [1],
[2], [3], [45].
The tentative diagnosis of a HNP has to be made pre-
operativelyinanycase,sothatthesurgeondoesnotface
the tumor unprepared. Matthews wrote all the way back
intheyear1915:“...thisraretumorpresentswithunusual
difficulties to the surgeon, and should one encounter it
without having suspected the diagnosis, the experience
will not soon be forgotten“ [94].
2.4.1 Therapy of cervical paragangliomas
Therapeutic options for the treatment of cervical HNPs
include complete surgical resection [1], [2], [3], [4], [19],
[48], [88], [95], conventional radiotherapy [47], [90],
[91], [92] and permanent embolisation [20], [37]. Due
to generally slow tumor growth, a “wait and scan” policy
might be justified in certain cases [1], [2], [3], [45].
In every case, benefits and potential risks of all the
treatment options mentioned have to be taken into con-
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sideration for every individual patient. Factors that play
animportantroleinthesearchforoptimaltherapyinclude
size, classification and exact localisation of the tumor(s),
age and general health of the patient as well as pre-
therapeutic cranial nerve deficits [1], [3], [48].
Surgical resection
Complete surgical resection represents the only curative
treatment option for HNPs [1], [4], [19], [49], [88]. The
first successful resection of a CBT dates back to 1889
(citedin[36]).Beforethedevelopmentofvascularsurgic-
al reconstructive techniques in the 1960s and 1970s
the results of sugical resection were miserable [37].
Mortality rates of 5-30 % have been reported in those
days (cited in [37]). Today, complete surgical resection
of cervical HNPs is considered the treatment of choice
for the vast majority of patients by most authors around
theworld[1],[2],[3],[4],[19],[48],[56],[88],[89],[95],
[96], [97], [98].
The resection of CBTs is performed via a transcervical
approach [36], [59], [95], [98]. Special care is taken to
avoid injury to the cranial nerves. Proximal and distal
control of the large vessels is then optained [36], [59].
Especially in Shamblin class III tumors, there might be
injury to the common or internal carotid artery. Therefore
thesurgeonshouldbefamiliarwiththeuseofintraluminal
vascular shunts as well as vascular reconstructive tech-
niques [59].
WhenweresectacervicalHNP,wealsoperformaselect-
ive neck dissection in the regions IIA, IIB and III [99] to
exclude or varify lymph node metastases [1], [59].
Cure rates after complete surgical resection of CBTs are
generally reported to be as high as 89-100% [1], [19],
[47], [88], [95]. The major morbidity associated with
surgeryisrelatedtopost-operativecranialnervedysfunc-
tion [1], [3], [17], [48], [100]. Patetsios et al. described
their experiences with the resection of CBTs. Permanent
post-operativecranialnervedeficitswereseeninfiveout
of 29 patients (17.2%) [48]. Wang and coworkers detec-
ted cranial nerve deficits in seven out of 29 patients
(24.1%)aftertumorresection[36].Anandandcoworkers
reviewed the post-surgical results of 1181 patients with
CBTs. Permanent cranial nerve deficits were seen in
21.8% of patients [100].
InpatientswithvagalPG,theaffectedvagalnerveusually
has to be sacrificed during surgery [3], [19].
Primary radiation
The aim of conventional radiotherapy in HNPs is to
achievelongtermtumorcontrol.Onehastokeepinmind
that radiotherapy of HNPs is not a curative treatment
option [47], [49].
Histopathologicstudiescoulddemonstratethatradiation
therapy does not have any effect on the chief cells but
leads to structural changes of the vascular connective
tissue [19], [48], [91].
Radiation of cervical HNPs is reported to achieve long
term tumor control in up to 96% of cases [47]. The dose
commonly recommended is 45 to 56 Gy. When doses of
less than 40 Gy are applied, failure rates have been
shown to be as high as 22% [101].
Permanentcranialnervedeficitsseemtobelesscommon
after radiation therapy of cervical HNPs when compared
to surgical resection [3], [47], [86]. Nevertheless, the
potential risk for radiation induced malignancies has to
be taken into serious account not only in young patients
[86], [102]. This potential risk has been estimated to be
as high as 3-5% [102].
In our opinion, radiation therapy of cervical HNPs should
be considered as a treatment option when a tumor is
clearly not resectable without reasonable risk, when the
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procedure or in the setting of multiple HNPs [1], [3].
Alternative therapeutic options
Due to slow tumor growth, a “wait and scan” policy may
be an option in selected cases [1], [3], [45], [59]. Tumor
doublingtimehasbeenestimatedtobebetween4.2and
13.8 years for HNPs [3], [86].
Persky and coworkers suggest a “wait and scan” policy
in old patients with multiple medical problems [3]. West-
erband et al. report on an asymptomatic 77 year old pa-
tient with a small CBT (diameter of 0.9 x 0.5 cm). Due to
the very small size, the authors decided to follow up the
patient in yearly intervals.
A so called permanent embolisation may have the poten-
tial to slow down tumor growth for a short period of time
[20], [37]. In our opinion, this option should only be con-
sidered in a clearly palliative setting.
2.4.2 Therapy of jugulotympanic
paragangliomas
The different treatment options have been a matter of
discussion in international medical literature when it
comes to treatment of jugulotympanic PGs. The current
treatment options include surgical resection [2], [19],
[46],[59],[103],[104],[105],[106],[107],conventional
radiation therapy [47], [90], [91], [92], stereotactic ra-
diosurgery[85],[86],[93],permanentembolisation[20],
[37] and a “wait and scan” policy [3], [59].
As in patients with cervical HNPs, benefits and potential
risks of all the treatment options mentioned have to be
taken into account for every individual patient. Factors
that play an important role in the search for optimal
therapy include size, classification and exact localisation
of the tumor(s), age and general health of the patient
and,especiallyinpatientswithjugularPGs,pre-therapeut-
ic cranial nerve deficits [1], [3], [48].
Surgical resection
The first (partial) resection of a jugular paraganglioma
was described by Rosenwasser in 1945 [cited in 49].
Until the development of microsurgical techniques, new
approachestotheskullbaseaswellasmoderninterven-
tional neuroradiology is was not possible to completely
resectjugularPGs[49].Potentiallylife-threateningvascu-
lar complications were frequently seen, the rate of post-
operative cranial nerve deficits was extremely high and,
due to incomplete resection, patients faced recurrent
tumor growth in the vast majority of cases [49].
Today local tumor control is achieved even in extensive
jugular PGs in 80-90% in most surgical series [3], [17],
[108], [109], [110], [111].
Compared to all other treatment options, surgical resec-
tion bears two major advantages. First of all, it is the only
curative treatment option [1], [3], [59]. In addition, it is
the only way to obtain material for histopathologic exam-
ination, since taking an open biopsy as well as FNA is
obsolete in those neoplasms [59].
For patients with tympanic PGs (Fisch class A and B)
completesurgicalresectionclearlyrepresentsthetherapy
ofchoicewhenevertherearenocontraindicationsagainst
a general anesthesia [3], [17], [46], [49], [59], [112].
Thosetumorsbecomesymptomaticbymeansofpulsatile
tinnitus and conductive hearing loss at an early stage in
the majority of cases. Complete surgical resection can
be optained in almost every case with a low risk for
damaging of the lower cranial nerves [46], [49], [59],
[112]. Schick and coworkers report on their results in
surgical resection of tympanic PGs [49]. Ten tympanic
PGs were resected in that study. There were no post-op-
erative cranial nerve deficits and the rate of tumor recur-
rance was 0% [49]. Gstoettner et al. did not detect any
cranialnervedeficitsafterresectionofsixclassBtympan-
ic PGs [46].
When it comes to optimal treatment of jugular PGs the
discussion in international medical literature is much
more controversial [3], [4], [47], [49], [90]. Fisch class C
and D jugular PGs are resected via an infratemporal ap-
proach in the majority of cases. In classes C1, C2 und
De,i1/2thejuxtacondylarapproachrepresentsanaltern-
ative. An intra-operative neuromonitoring of the cranial
nervesVII,IX,X,XIandXIIhasbeenshowntobeofbenefit
in patients with class C and D jugular PGs [59]. When it
comes to class Di3 tumors, the attempt of a surgical re-
section does not make any sense. Those patients should
be send for palliative radiation therapy [59].
The downside of surgical resection of jugular PGs is the
large percentage of post-operative cranial nerve deficits.
As jugular PGs are intimately involved with the lower
cranial nerves, patients frequently suffer from post-oper-
ativefacialpalsyaswellasvoice,swallowing,articulation
and shoulder weakness problems [3], [19], [49], [108],
[109], [110].
Perskyetal.detectedpost-operativecranialnervedeficits
in 10 out of 14 patients with jugular PGs (71.4%) [3].
Schick et al. described new cranial nerve deficits after
resection of 32 class C and D jugular PGs as often as: N.
VII in 37.9%, N. IX in 31%, N. X in 45.8%, N. XI in 7.1%
and N. XII in 36% of cases [49]. Additional surgical pro-
ceduressuchasvocalcordmedializationandotherswere
required in 15 out of 32 patients in this study (46.9%)
[49].
Due to the fact that older patients find it more difficult to
copewithpost-operativecranialnervedeficits,Glasscock
and coworkers suggested a maximum age of 60 years
for the surgical resection of jugular PGs [113]. In our
opinion though, the age of a patient alone should not be
the only reason whether surgical resection should be
suggested to the patient or not.
Primary radiation
One advantage of conventional radiation therapy has
been said to avoid the morbidity of surgery while offering
a high probability of local tumor control [47], [90], [91],
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rate of 90% after radiation of 46 patients with jugulotym-
panic PGs. Median follow-up in this study was nine years
[92]. Chino et al. reported on long-term follow-up in a
group of 31 patients with jugulotympanic PGs. Local
controlrates5years,10yearsand15yearsaftersurgery
where96%,90%and90%respectively[114].Boyleeven
reported a tumor control rate of 100%. Unfortunately,
there are only nine patients in this study and follow-up
timewasveryheterogenous,rangingfromoneto12years
[90].
Lower cranial nerve deficits after radiation therapy do
occurlessfrequentlyafterradiationcomparedtosurgery
[3], [47], [86]. In the study by Powell et al. a facial nerve
palsywasdetectedin2/46patients(4.7%)afterradiation
of a jugulotympanic PG [92]. In a group of 53 patients
reported by Hinerman and coworkers, there was a facial
palsy in just one patient (1.9%) [47].
Nevertheless, a number of serious complications have
been reported after radiation of jugular PGs including
temporal bone osteomyelitis, necrosis of the temporal
lobe as well as insufficiency of the pituitary gland [47],
[49], [86]. More frequently seen but less dramatic side
affects of temporal bone radiation include chronic otitis
media, chronic stenosis of the external ear canal as well
as chronic problems in the maxillary joint. Those kind of
„minor“complicationswereseenin5/53patients(9.4%)
reported by Hinerman [47].
Inadditiontothefactthatradiationtherapyofjugulotym-
panic PGs represents no curative but only a palliative
treatment option, the potential risk for radiation induced
malignancies has to be taken into serious account not
only in young patients [86], [102].
In addition, surgical resection is more difficult in cases
where local tumor control is not achieved by radiation
therapy [49].
Stereotactic radiosurgery
Stereotactic radiosurgery („gamma knife“) represents a
rather new treatment option for patients with jugulotym-
panic PGs [85], [86], [93]. In contrast to conventional
radiotherapy, the whole radiation dose of 12-18 Gy may
be applied within a single day [85]. Foote et al. report on
their experiences with stereotactic radiosurgery in the
treatment of 25 patients with jugulotympanic PGs [86].
Duringamedianfollow-uptimeof37monthstheauthors
did not detect any tumor growth in those patients. Addi-
otionally, there were no cranial nerve deficits due to
therapy. Feigenberg and coworkers on the other hand
report on two out of five patients that presented with
growingjugulotympanicparagangliomasafterstereotactic
radiosurgery [85]. One patient in that study also de-
veloped a deficit of the trigeminal nerve.
Concerning stereotactic radiosurgery, we agree with
Hinerman that larger studies with a longer follow up are
neededtojudgetheoppertunitiesofthistreatmentoption
in the therapy of jugulotympanic paragangliomas [93].
Alternative therapeutic options
AsinpatientswithcervicalPGs,tumorgrowthisalsoslow
in the majority of jugulotympanic PGs [49], [59]. There
are reports of patients in the literature that survived
without any kind of treatment for more than 40 years
[115].
A „wait and scan“ policy is always to be considered in
elderly patients with underlying medical conditions or
very small tumors as well as in patients with small recur-
rent tumors after therapy [59].
Apermanentembolisationonlyhasapalliativecharacter
[20], [37].
In the last few years, there have been promising results
of heavy ion therapy in the treatment of benign and ma-
lignant neoplasms of the skull base [116], [117], [118].
Heavy ion therapy is a treatment option that may play a
futureroleinpatientswithrecurrentandextensivejugular
PGs.
2.4.3 Recommendations for therapy
OurtherapyrecommendationsforpatientswithHNPsare
listed in Table 3.
In our opinion, the majority of patients with HNPs should
undergo complete tumor resection. One has to keep in
mind,thatcompleteresectionrepresenttheonlycurative
treatment option for those unusual neuroendocrine neo-
plasms.
The recommendations in Table 3 are only valid for pa-
tientsthatmaybeoperatedingeneralanesthesiawithout
any major risks. Especially in large vagal PGs, class III
CBTs as well as class C and D jugular PGs a number of
additional factors have to be considered when therapy
is planned on an individual basis for every patient. Those
factorsincludetheageandgeneralhealthofthepatient,
size, class and localisation of the tumor(s) as well as pre-
operative cranial nerve deficits.
2.4.4 Therapy of multifocal paragangliomas
Patients with multifocal HNPs represent a special chal-
lenge[1],[18],[20],[59],[119],[120].Aonestepsurgery
in subjects with bilateral HNPs is usually obsolete since
it is bearing the risk of bilateral cranial nerve palsies
resulting in severe disabilities [1], [18], [20], [59], [119],
[120]. Velegrakis et al. recommend to always resect the
largesttumorfirst.TheremainingHNP(s)canbeobserved
or, if needed, treated by radiation therapy or permanent
embolisation[119].Sobolandcoworkersthinkthataone
stepsurgicalproceduremaybeanoptioninpatientswith
multiple unilateral HNPs. They report on a 27 year old
patientwithaCBTandavagalPGontherightside.During
the resection of the vagal PG, the vagal nerve had to be
sacrificed. The class I ipsilateral CBT could be resected
without problems during the same surgery [18].
Based on our experiences in the treatment of multifocal
HNPs we recommend to resect the largest tumor first
whenever possible [20], [59], [120]. Depending on the
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post-operativecranialnervestatus,therapyoftheremain-
ing tumor(s) may be individually planned. In the case of
a 45 year old patient with bilateral jugular PGs, we could
completely resect both tumors without the occurance of
cranial nerve deficits within one year [120]. The same
was true for a 34 year old patient with bilateral CBTs [1].
A 38 year old patient presented with a palsy of the vagal
and hypoglossal nerve after resection of a class III CBT.
The two remaining contralateral HNPs therefore under-
went radiation therapy [20].
Patients with bilateral vagal PGs are somewhat of a spe-
cial issue. Since it is usually not possible to resect those
tumors without sacrificing the vagal nerve, we suggest
resection of the larger tumor followed be radiation of the
remaining paraganglioma.
2.4.5 Follow-up
Nomatterwhatkindoftherapyhasbeenapplied,patients
with HNPs need long time follow-up. Forrest et al. recom-
mend yearly intervals within the first five years after
therapy. Thereafter intervals may be stretched to three
to five years [112]. At our department, patients are seen
every six months during the first five years. After that,
patients come in once a year. All patients undergo a
thoroughexaminationoftheheadandneckduringthose
follow-ups. In patients with cervical HNPs be perform a
bilateral B-mode sonography with color-coded duplex
sonography. Whenever needed, an MRA is performed in
addition. Patients with jugulotympanic HNPs undergo an
MRI and an MRA.
Especially patients with jugular PGs need life long follow-
up. Recurrent tumors have been seen in those patients
decades after initial treatment.
2.5 Preoperative embolisation
The primary goals of pre-operative embolisation of HNPs
are to reduce blood loss in the surgical field, minimize
the risk of intraoperative complications, prevent recur-
rence by contributing to complete resection as well as
minimizing the need for blood transfusions [4], [37],
[121].
Since embolisation is an invasive and potentially danger-
ous procedure, the risk of potential complications from
embolisation always have to be weighed against the ad-
vantages. An experienced vascular neuroradiology team
has to be absolutely familiar with the complexities and
possible variations in head and neck vascular anatomy.
At the Department of Neuroradiology of Freiburg Medical
School different polyvinyl alcohol (PVA) particles with
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for embolisation of HNPs. Occasionally, coils may be
useful in addition. Proper timing of pre-operative embol-
isation is needed. In our opinion, embolisation should be
performedbetweentwoandfourdaysbeforesurgery[1],
[4].
Possible minor side effects of embolisation include fever
as well as local pain and hematomas in the groin. Severe
sideeffectsincludeskinnecrosis,blindness,cranialnerve
deficitsandalargenumberofneurologicaldeficitsinclud-
ingunilateralpalsyanddeath[3],[20],[36],[122],[123],
[124]. Miller et al. did not observe any neurological defi-
cits after embolisation of five vagal PGs [17]. The same
was true for a group of six HNP patients reported by
Frühwirtandcoworkers[37].Perskyandcoworkersreport
on 47 patients with 53 HNPs. All tumors in that study
underwent pre-operative embolisation. Complications
were seen in six patients (12.8%). Those complications
included two vagal verve palsies, one jugular foramen
syndrome, one facial nerve palsy, one temporary unilat-
eralpalsyandoneasymptomaticdissectionoftheverteb-
ral artery [3].
Pre-operative embolisation of cervical paragangliomas
The embolisation of a CBT was first described by Schick
in 1980 [125]. The arterial supply of CBTs and vagal PGs
typicallyderivesfromtheexternalcarotidartery.Branches
from the ascending pharyngeal artery, the posterior auri-
cular artery as well as the occipital artery usually form
themainarterialfeedingvessels[37].Itisofgreatimport-
ance to be aware that there may be a great variety of
blood supply in cervical HNPs though [3]. The question,
whether cervical HNPs should be routinely embolised is
a matter of controversial discussion [1], [4], [36], [37],
[48], [87], [126], [127]. Many authors are in favor of
embolisation of CBTs and vagal PGs [1], [4], [36], [37],
[59], [126], [127]. Miller et al. report on a group of 19
patientswithvagalPGs.16ofthosetumorswereresected
andfivetumorsunderwentembolisationbeforeresection.
Inthosefivepatientsintra-operativebloodlosswasmuch
smaller and time in the operating theatre was shorter.
There was also a smaller incidence of post-operative
cranial nerve deficits in this group of patients [17]. Wang
et al compared a group of 17 CBTs that underwent em-
bolisation with a group of 12 CBTs that were not embol-
ised. The intra-operative blood loss was significantly
smaller in the group of CBTs that had undergone embol-
isation[36].Basedonownexperienceswithpre-operative
embolisation of 28 CBTs, Persky and coworkers also
strongly recommend this approach [3].
Pre-operative embolisation of jugulotympanic
paragangliomas
The first embolisation of a jugular PG was described by
Hekster in 1973 [128]. The arterial tumor supply in jugu-
lotympanic PGs depends on the tumor stage. Class A
tympanicPGsareusuallysuppliedviatheinferiortympan-
ic artery. Class B tympanic PGs usually get their blood
supply via branches of the ascending pharyngeal artery.
In class C jugular PGs the main blood supply is via the
ascending pharyngeal artery as well as the maxillary, oc-
cipital and temporal arteries. Class D jugular PGs usually
have a very individual blood supply [59]. It is of great im-
portance to be aware that there may be a great variety
of blood supply in patients with jugulotympanic HNPs
though.
The pre-operative angiographic embolisation represents
the international gold standard in treatment of class C
and D jugular PGs [3], [46], [49], [59], [129], [121].
Without embolisation, it would not be possible to com-
pletely resect those tumors in the vast majority of cases
[46].
Recommendations for pre-operative embolisation of
paragangliomas
Our recommendations regarding embolisation of HNPs
are summarized in Table 4.
Table 4: Recommendations regarding preoperative
embolisation
In class I and II CBTs a pre-operative embolisation is not
mandatory. Those patients should be clearly informed
about potential benefits and risks of embolisation. We
strongly do recommend embolisation in Shamblin class
III tumors though.
For vagal paragangliomas the question concerning the
need for embolisation may only be answered on an indi-
vidual basis.
Class A tympanic PGs must not be embolised whereas
embolisation may be useful in selected cases of class B
tympanic paragangliomas.
Class C and D jugular paragangliomas on the other hand
must undergo pre-operative embolisation whenever sur-
gical resection is performed.
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Interestingly, there are no histopathological or immuno-
histochemical criteria for the diagnosis of a malignant
paraganglial tumor. Therefore, a malignant HNP or
pheochromocytoma may only be diagnosed when there
is metastasis to non neuroendocrine tissue [1], [3], [4],
[6], [18], [48]. In HNPs, metastases are most frequently
found in cervical lymph nodes. Distant metastases are
most common in bone, liver and lung [44], [74], [75],
[76], [77], [78], [79].
Overall, less than 10% of all HNPs have been cited to be
malignant[1],[3],[6],[48].Malignancyseemstobemost
common in vagal PGs (16-19%) when compared to CBTs
(6%) and jugulotympanic PGs (2-4%) [6].
MalignantHNPsareoftenreportedassinglecasereports
in the literature [44], [52], [74], [75], [77], [78], [130],
[131]. Concerning the incidence of malignancy in HNPs,
the publication of large groups of PG patients is more in-
teresting [3], [17], [19], [48], [95]. Miller et al. detected
three malignant tumors in a group of 19 patients with
vagal PGs (15.8%). Two patients presented with regional
lymph node metastases, one patient had systemic dis-
easetothesacrum[17].Patetsiosetal.reportedonthree
malignant HNPs in a group of 29 CBT patients (10.3%)
[48]. Two patients had cervical lymph node metastases,
one presented with intrahepatic metastatic disease.
Grotemeyer et al. diagnosed four malignant tumors in a
groupof39HNPpatients(10.3%)[95].Inthelargeseries
(n=79 HNP patients) reported by Kollert et al. there were
no signs of metastatic disease in any patient [19].
The largest study to date dealing with malignant HNPs
waspublishedbyLeein2002[6].Forthisstudy,thedata
ofthe“NationalCancerDataBase”from1985until1996
was studied. There were 59 malignant paragangliomas
in a group of 355019 patients (0.017%). There were 30
female (50.9%) and 29 male patients (49.1%). Median
age at the time of diagnosis was 44 years. 68.7% of pa-
tients presented with cervical lymph node metastases,
31.3% of patients had systemic metastases. Five year
survival was 59.5%. There was a significant difference
betweenpatientswithlocalmetastasesandpatientswith
systemicdiseasethough.76.8%ofpatientswithregional
lymph node metastases were alive after five years com-
pared to only 11.8% in the group with systemic meta-
stases.TherapyofchoiceinpatientswithmalignantHNPs
is complete tumor resection with resection of all meta-
stases whenever possible [6]. Radiation therapy is a
sufficient tool to significantly prolong survival whenever
completeresectionisnotachieved.Mediansurvivaltime
in patients who underwent radiation was 45 months
versus 12 months in the group of patients without radi-
ation [6].
Benefits of chemotherapy in the treatment of malignant
HNPs are a matter of controversial discussion in the liter-
ature. Many authors do not see any benefit for this kind
of treatment [6], [44], [74], [76]. Argiris and coworkers
reported on their experience with a 33 year old female
patientsufferingfromaCBTwithpulmonaryandosseous
metastases. The patient underwent chemotherapy with
cyclophosphamide, adriamycin and dacarbazin leading
to partial remission of disease [8]. One has to keep in
mind though, that the course of disease is indolent and
hard to predict in patients with metastatic HNPs. There
arereportsofpatientswithmalignantHNPsintheliterat-
ure who survived for decades without any kind of treat-
ment [132].
There have been promising initial results in the therapy
of patients with widespread metastatic disease from
paraganglial tumors using radiolabeled somatostatin
analogs such as 111In-octreotid, 131I-metaiodobenzyl-
guanidin(131I-MIBG)and177LU-DOTATATE[133],[134],
[135]. Nervertheless, prognosis remains poor for HNP
patients with systemic metastases.
RecommendationsregardinglymphadenectomyinHNP
patients
Cervical lymph node metastases are not an uncommon
feature in patients with cervical HNPs. Therefore we per-
form an ipsilateral selective neck dissection in levels II
andIIIinpatientsundergoingresectionofacervicalHNP.
When we resect a jugular paraganglioma we do a
lymphadenectomy in the upper region of the ipsilateral
jugular vein. In patients with tympanic PGs we usually do
not perform any kind of lymph node resection. The risk
for lymph node metastases is considered very low for
those tumors of the middle ear [4].
2.7 Hereditary paragangliomas and
pheochromocytomas
HNPs as well as pheochromocytomas may occur as
sporadic or familial entities [136], [137], [138], [139],
[140], [141], [142].
It has been well known for decades that familial pheo-
chromocytomas are part of different tumor syndromes
[132], [139], [143], [144], [145], [146]. Pheochromocyt-
omas do occur in 30 to 50% of patients with multiple
endocrine neoplasia type 2 (MEN2) [132], [146], [147],
[148], [149]. 10-20% of patients with von Hippel-Lindau
syndromepresentwithpheochromocytomas[132],[146],
[149],[150]andtherisktodeveloppheochromocytomas
is estimated to be 1-5% for patients with neur-
ofibromatosis type 1 (NF 1) and around 1% for subjects
with multiple endocrine neoplasia type 1 (MEN1) [146],
[149].
The familial clustering of HNPs has also been described
in international medical literature for decades. In 1933,
Chasefirstdescribedtwosisterswhobothpresentedwith
CBTs [151]. Goekopp mentioned the occurance of jugu-
lotympanic paragangliomas in three sistern the same
year [152]. The first description of familial vagal
paragangliomas dates back to 1956 [153].
Although so called „paraganglioma syndromes“ (PGL)
have been described for many years, they have not been
classifiedbasedonmoleculargeneticsuntilthebeginning
of this century. In 2000, Baysal et al. first identified
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subunit D gene (SDHD gene) as the underlying cause of
PGL 1 [139]. PGL 3 is associated with SDHC and PGL 4
withSDHBgenemutations[154],[155].ThegenesSDHB,
SDHC and SDHD are all tumor suppressor genes [155],
[156], [157], [158], [159]. PGL 2 is caused by mutations
ofthesuccinatedehydrogenasecomplexassemblyfactor
2 gene (SDHAF2 gene) which is also known as SDH5
[160], [161]. PGL 2 has only been characterized on a
molecular genetic basis in 2009 [160].
Succinatedehydrogenase, consisting of the subunits
SDHA, SDHB, SDHC and SDHD, forms the mitochondrial
complex II. It plays an important role in the mitochondrial
respiratory chain as well as the tricarboxylic acid cycle
[41], [144], [156], [162], [163], [164], [165].
The molecular genetic screening for mutations of the
genes SDHB, SDHC and SDHD require 10ml of EDTA an-
ticoagulated blood as well as a written informed consent
[9]. The screening for all three genes, SDHB, SDHC and
SDHD, costs approximately 2700 US$ per patient. The
DutchgrouparoundvanNederveendevelopedanelegant
and cheap immunohistochemical examination for the
detection of SDHx mutations. Sensitivity and specifity of
the SDHB immunohistochemistry is 100% and 84% re-
spectively [166]. Obviously, this method can only be ap-
plied after surgery. It is only possible to predict whether
there is an SDHx mutation or not. The method can not
tell which kind of SDHx mutation there is.
Table 5 shows all tumor syndromes characterized on a
molecular genetic basis until October 2010 that are as-
sociated with HNPs and/or pheochromocytomas.
2.7.1 MEN1
Multiple endokrine neoplasia type 1 (MEN1) is an auto-
somal dominant disease caused by mutations of the
MEN1 gene. MEN1 consists of 10 exons and it encodes
the 610 amino acid protein menin [174]. Disease pen-
etranceisnearlycompleteandpatientswithMEN1typic-
allydeveloptumorsoftheparathyroidglands,thepancre-
atic islet cells and the anterior pituitary gland. Less pre-
valent neoplasms associated with MEN1 are carcinoid
tumors,facialangiofibromas,lipomasandcollagenomas.
Pheochromocytomas are only seen in about 1% of pa-
tients with MEN1 [146], [149]. HNPs have not been de-
scribed in association with MEN1 yet.
2.7.2 MEN2
MEN2 is an autosomal dominant syndrome associated
with mutations of the RET gene. The RET gene consists
of 21 exons [167]. All RET mutations described in the
literature to date may be found on http://arup.utah.edu/
database/MEN2/MEN2_display.php?sort=1. There are
a total of three subtypes. The most common subtype,
MEN2A,ischaracterizedbymedullarythyroidcarcinomas
(MTC), pheochromocytomas and parathyroid neoplasia.
PatientswithMEN2Bpresentwithearlyonsetaggressive
MTC, pheochromocytomas and characteristic physical
features such as a marfanoid habitus as well as neurino-
mas of the tongue, conjunctivas and the colon. FMTC
(familial medullary thyroid cancer) is the third subtype in
which MTC is the sole manifestation [167], [168].
About30to50%ofMEN2patientsdeveloppheochromo-
cytomas [132], [146], [147], [148], [149]. HNPs have
only been described in the three subjects with MEN2 so
far [20], [169], [170].
2.7.3 NF1
Neurofibromatosistype1(NF1)isanautosomaldominant
tumor syndrome caused by mutations of the NF1 gene
[171]. The NF1 gene, consisting of 57 exons, is one of
the largest human genes. The disease phenotype is
dominated by multiple neurofibromas of the skin, café-
au-laitspots,axillaryfrecklingandsocalledLischnodules
of the iris. NF1 patients are also at risk for the develop-
ment of multiple tumors deriving from nerve tissue and
endocrinetissues.1-5%ofNF1mutationscarrierspresent
with pheochromocytomas [132], [146], [149], [172],
[171]. A HNP in association with NF1 has only been de-
scribed in one caes yet [173].
2.7.4 VHL
Von Hippel-Lindau syndrome (VHL) is a multisystemic
autosomaldominantdiseaseduetomutationsoftheVHL
gene [169], [174], [175], [176], [177]. The VHL gene
consistsofthreeexons.Theencodedproteinhasgot213
aminoacids.AllVHLmutationsdescribeduptodatemay
be found at http://www.umd.be/VHL/. VHL displays full
penetrance by age 65 although the individual disease
phenotypeishighlyvariable.Thetumorsmostcommonly
seen in VHL mutation carriers are hemangioblastomas,
retinal angiomas, renal cell cysts and renal cell carcino-
mas, pancreatic cysts as well as pheochromocytomas
[174]. Occasionally endolymphatic sac tumors (ELST),
among others, may also be observed [178].
Between 10 and 20% of all VHL patients present with
pheochromocytomas[132],[146],[149],[150].Thefact,
that VHL mutation carriers are also at risk for the devel-
opmentofHNPshasfoundlittleattentionininternational
medical literature for many years. Until the year 2009
there were only five single case reports of patients with
a HNP and VHL syndrome [179], [180], [181], [182],
[183].In2009,ourgroupconductedalargeinternational
multicenter study including a total of 2084 registered
VHLpatients.Elevenofthosepatients(0.53%)hadaHNP
[169]. In a later work, Gaal et al. could demontrate that
HNPs are part of VHL and are due to VHL gene inactiva-
tion in those patients [175].
2.7.5 Paraganglioma syndromes (PGL)
Since the description of SDHD gene mutations as the
cause of PGL 1 by Baysal et al. in the year 2000 [139],
the paraganglioma syndromes (PGL) have attracted a lot
of scientific attention.
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Inthemeantime,severallargeinternationalstudiescould
demonstrate that approximately 30% of all seemingly
sporadic HNPs are due to genetic mutations [9], [10],
[143], [184], [185], [186], [187]. The large majority of
those hereditary HNPs is due to the paraganglioma syn-
dromes 1, 3 and 4. HNPs in association with PGL 2 and
VHL are less common [160], [161], [169] and in patients
with MEN2 and NF1 head and neck paragangliomas are
only very rarely seen [169], [173].
The PGL are characterized by distinct clinical features
[9], [10], [143], [184], [185], [186], [187], which will be
briefly shown.
PGL 1
Paraganglioma syndrome 1 (PGL 1) is caused by SDHD
gene mutations [139]. In the SDHD gene, there are 4
exons and the encoded protein has 160 amino acids. All
differentSDHDgenemutationsdescribedintheliterature
so far may be found at http://chromium.liacs.nl/lovd_
sdh/variants.php?action=search_unique&select_db=
SDHD.
PGL 1 is the most common paraganglioma syndrome.
SDHD mutation carriers are at risk for the development
of both HNPs and pheochromocytomas, although HNPs
are much more commonly seen. Pasini and Stratakis re-
viewed a total of 95 international manuscripts dealing
with SDHx mutations [142]. There were a total of 395
SDHD patients in this review. 91% of those patients dis-
played at least one HNP and 79% even presented with
multiple HNPs. Malignant paraganglial tumors are seen
on a regular basis in SDHD mutation carriers although
malignancy is significantly more common in SDHB pa-
tients [142]. Neumann et al. presented the results of a
large multicenter study in 2009 [10]. A total of 598 pa-
tients with apparently sporadic HNPs were screened for
mutations of the genes SDHB, SDHC and SDHD. Muta-
tions were detected in a total of 183 subjects (30.6%).
There were 94 SDHD mutations carriers as well as 63
SDHBand26SDHCpatients,respectively.SDHDpatients
presented with multiple HNPs in 56 out of 94 cases
(59.6%). HNPs and pheochromocytomas were seen in
17cases(18.1%)whereasmalignantparaganglialtumors
hadtobediagnosedin9SDHDmutationcarriers(9.6%).
The family history was positive in 45 patients which is
47.9% of cases.
Tumor penetrance in SDHD mutation carriers is high.
Neumann et al. first published data on age related pen-
etrance in SDHD mutation carriers in 2004 [9]. SDHD
mutations conferred 50% penetrance by age 31 rising to
86% by the age of 50 in that study. In a 2010 study by
Hensen and coworkers, age related penetrance in SDHD
patients was 54% by age 40 and 87% by age 70 [186].
The trait of inheritance in SDHD mutation carriers is
autosomal dominant with a „parent-of-origin-dependent-
inheritance“ [9], [132], [139], [164], [188]. This means
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the development of paraganglial tumors if they inherited
the mutation from their father. Though not at risk for tu-
mor development themselves, SDHD mutation carriers
whoinheritedthemutationthroughthematernallinewill
still pass the mutation to their children in 50% of cases.
PGL 2
PGL 2 is associated with mutations of the SDHAF2 gene
[160], [161]. SDHAF2, also known as SDH5, consists of
4exons.Itplaysanimportantroleinflavinationofsuccin-
ate dehydrogenase subunit A [161].
In 1982, van Baars et al. described a large Dutch family
(295 living family members) with familial HNPs [189].
The PGL in this family has later been referred to as PGL
2 [7], [161]. It was not until the year 2009 though, that
Hao et al. identified a mutation of the SDHAF2 gene as
the underlying cause of PGL 2 [189].
Bayley and coworkers detected another family with PGL
2, this time in Spain [161]. The authors also looked for
SDHAF2 mutations in 443 additional HNPs and pheo-
chromocytoma patients without finding another case of
PGL 2.
InbothfamilieswithPGL2onlyHNPsbutnopheochromo-
cytomas have been described [161], [189]. As in PGL 1
there is also a “parent-of-origin-dependent-inheritance”
in SDHAF2 mutation carriers [161]. Tumor penetrance
has been described to be very high in both the Dutch as
well as the Spanish family [161], [189].
PGL 3
PGL 3 is caused by SDHC gene mutations [154]. The
SDHCgeneconsistsof6exonsandencodesa169amino
acid protein [142]. The SDHC mutations described so far
are listed at http://chromium.liacs.nl/lovd_sdh/
variants.php?action=search_unique&select_db=SDHC.
Nieman et Müller first identified an SDHC mutation as
theunderlyingcauseofPGL3[154].UntilOctober2005,
only four patients with SDHC mutations had been de-
scribed [154], [159], [190], [191]. Many authors con-
cluded that SDHC mutations must be exceedingly rare
and therefore, HNP patients were not routinely tested for
mutations of the SDHC gene. This only changed when
Schiavi et al. reported on a total of 22 SDHC mutation
carriers in October 2005 [184]. Due to the following in-
creased rate of SDHC testing, many SDHC mutations
could be detected in the years following 2005. Neverthe-
less, SDHC mutations are still less common than SDHD
and SDHB mutations.
InsharpcontrasttopatientswithPGL1andPGL4,SDHC
mutation carriers almost exclusively develop benign,
singleHNPs[10],[184].Malignantparagangliomas[159]
andpheochromocytomas[192],[193],areonlyveryrarely
seen in SDHC patients.
In a 2009 study by Neumann and coworkers, there were
26 subjects with SDHC mutations in a total of 598 HNP
patients [10]. There were no pheochromocytomas and
no malignant HNPs in that SDHC group of patients. 21
out of 26 patients (80.8%) presented with a single HNP,
five patients had two HNPs.
SDHC mutations follow an autosomal dominant trait of
inheritance [5], [156], [159], [184]. Penetrance is prob-
ably rather low. In the study by Neumann et al., family
history has only been positive in three out of 26 SDHC
patients (11.5%) [10].
PGL 4
PGL 4 is caused by mutations of the SDHB gene [155].
The SDHB gene consists of 8 exons and the protein en-
coded has 280 amino acids [142]. The site http://
chromium.liacs.nl/lovd_sdh/variants.php?action=search_
unique&select_db=SDHB lists all SDHB mutations that
have been published so far.
The first description of the SDHB mutation as the cause
of PGL 4 dates back to 2001 [155].
Patients with PGL 4 frequently develop HNPs and pheo-
chromocytomas. In contrast to SDHD mutation carriers,
patients with SDHB mutations develop pheochromocyto-
mas significantly more often than HNPs [142], [185],
[193],[194].MultipleHNPsaresignificantlylessfrequent
when compared to SDHD patients [10], [142].
ThemoststrikingclinicalfeatureofPGL4istheveryhigh
percentageofmalignantpheochromocytomasandmalig-
nant HNPs [9], [10], [137], [142], [185]. In the study by
Neumannetal.thereweremalignantparaganglialtumors
in 13 out of 63 SDHB mutation carriers (20.6%) [10].
Ricketts et al. reported on 40 SDHB patients with malig-
nantparagangliomasandpheochromocytomasinagroup
of 163 SDHB mutation carriers (25.2%) [185]. In a liter-
ature review by Pasini and Stratakis, malignant
paraganglial tumors were diagnosed in 105 out of 256
SDHB mutation carriers (41%) [142]. In addition, PGL 4
patients are at an incresed risk for the development of
kidneycancers.In2004,VanharantadescribedtwoSDHB
patients who developed malignant kidney tumors at age
24 and 26 [195]. Ricketts et al. estimate the risk for
subjects with PGL 4 to develop a malignant renal tumor
by age 70 to be as high as 14%.
SDHB mutations follow an autosomal dominant trait of
inheritance [5], [9], [10], [155]. Tumor penetrance is
somewhat lower than that seen in SDHD mutation carri-
ers. Recent studies estimated the age related tumor
penetrance in SDHB mutation carriers to be at 29% at
age 30 rising to 45% at age 40 [196].
Differences between PGL and sporadic HNPs
Patients with paraganglioma syndromes develop
paraganglial tumors at a significantly younger age than
patients with sporadic HNPs and sporadic pheochromo-
cytomas[5],[142],[197].Burnichonetal.compared242
tumor patients with SDHB, SDHC and SDHD mutations
with a group of 203 subjects with sporadic paraganglial
tumors [197]. The age at first manifestation of a
paraganglial tumor was 36.2 years in the PGL group
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(p<0.0001). Multiple paraganglial tumors were also sig-
nificantlymorefrequentinSDHxmutationcarriers(n=112
versus n=10; p<0.0001). PGL patients also had a signi-
ficantly higher risk for the development of malignant
paraganglial tumors (n=40 versus n=9; p<0.0001), al-
though this difference was greatly due to the very large
percentage of malignant tumors in the SDHB subgroup
[197].
Tumor development in PGL
Development of sporadic CBTs has been linked to
chronic hypoxic stimulation of the glomus caroticum as
it can be seen in patients living at high altitudes and in
subjectswithchronicobstructivelungdisease[36],[42],
[43].
The role of SDHB, SDHC and SDHD as tumor suppressor
genes has been clearly defined. Mutations in one of the
three genes lead to complete loss of function of SDH
[142], [158]. Thus inactivation of SDHB, SDHC or SDHD
with subsequent loss of SDH function results in a
pseudohypoxic state. The resulting activation of hypoxia-
induciblefactors(HIF)pathwayshasbeenlinkedtoaccu-
mulation of succinate and resulting inhibition of prolyl
hydroxyase enzymes that are needed for proteosomal
degradation of HIF-alpha subunits. This is believed to
lead towords cell proliferation, angiogenesis and tu-
morgenesis in paraganglial tissue [185].
2.7.6 Additional genes of interest
The majority of familial HNPs is associated with PGL 1,
3 and 4. Pasini and Stratakis reviewed the studies con-
cerning SDHx mutations and paraganglial tumors that
were available in 2009 [142]. 87.8% of familial HNPs
described in the literature up to then had been due to
mutationsinthegenesSDHB,SDHCandSDHD.Thefact,
that a certain percantage of clearly familial HNPs does
not seem to be associated with PGL 1, 3 and 4, VHL or
PGL 2 makes it very likely that other genes probably play
a role in the development of HNPs and pheochromocyto-
mas [142], [157].
Inthiscontext,twopromisinggenesofinteresthavebeen
described in 2010.
SDHA
The SDHA gene consists of 15 exons and encodes a 664
amino acid protein that forms the SDHA subunit of SDH
[142],[163].SDHAmutationsfollowanautosomalrecess-
ive trait of inheritance [163]. Interestingly, as the only
subunit of SDH, SDHA mutations had not been linked to
paraganglial tumors but to a familial neurologic disorder
called the Leigh syndrome [161], [198]. Burnichon and
coworkers first described a 32 year old SDHA mutation
carrier who developed a pheochromocytoma in 2010
[157]. Right now, it is too early to predict what kind of
role SDHA mutations with play in the future of hereditary
paraganglial tumors though.
TMEM127
Qin et al. described mutations of the TMEM127 gene in
patients with hereditary pheochromocytomas in 2010
[199]. Again, it is not possible yet to predict how many
patients with paraganglial tumors really do suffer from a
TMEM127 mutation.
2.7.7 Carney triad
In 1977, Carney et al. reported on two patients with sar-
comas of the stomach (today referred to as gastrointest-
inalstromaltumororGIST),extraadrenalpheochromocyt-
omas and pulmonary chondromas [200]. Since the year
1981, this tumor complex is known as the Carney triad
[201]. Patients with the triad are also at risk for the de-
velopment of paragangliomas and esophageal
leiomyomas [200].
In 1999, Carney reviewed the literature and found a total
of79patientswhowerediagnosedwiththeCarneytriad.
Two of those 79 subjects were later outsourced from this
group of patients by Carney and Stratakis and were dia-
gnosedwiththeCarney-Stratakissyndrome[202][.Inter-
estingly,noneoftheremaining77patientshadapositive
family history for the Carney triad or even for one of its
associated tumors. Moreover, none of the 355 first de-
gree relatives had the triad or even one of its tumors
[203], [202]. Therefore the potentially hereditary status
of the Carney triad remains at best unclear.
2.7.8 “Carney-Stratakis syndrome”
Carney and Stratakis reported on five families in 2002
presenting with GIST, paragangliomas as well as pheo-
chromocytomas [202]. This association of tumors is also
referred to as the „Carney-Stratakis syndrome“ in the lit-
erature [142], [204]. In the meantime, it could be
demonstratedthatthemajorityofpatientswhohadbeen
diagnosedwith„Carney-Stratakissyndrome“reallysuffer
frommutationsinoneofthegenesSDHB,SDHCorSDHD
[142].Therefore,wedonotconsiderthe„Carney-Stratakis
syndrome“ to be a real syndrome. It is more likely that
patients with PGL 1, 3 and 4 also develop GIST occasion-
ally.
2.7.9 Molecular genetic screening
According to the 2003 policy statement from the Americ-
an Society of Clinical Oncology for cancer genetic testing
allpatientswhoareatariskofmorethan10%toharbour
a genetic mutation should undergo molecular genetic
testing [205].
After the molecular genetic characterization of the
paraganglioma syndromes 1, 3 and 4 in the years 2000
and 2001 there was a lack of international standards
regarding the question who should be tested for SDHx
mutations. In 2002, Young and coworkers suggested a
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according to Neumann et al. [10].
screening for all HNP and pheochromocytoma patients
with a positive family history [132]. Neumann et al. pub-
lished the molecular genetic screening results of 271
patients with apparently sporadic pheochromocytomas
in 2002 [143]. In 24% of cases there was a mutation in
one of the genes SDHB, SDHD, VHL and RET. Therefore,
Neumann strongly recommended a screening of all
pheochromocytoma patients for mutations of the genes
SDHB, SDHD, VHL and RET [143]. Based on own results,
Gimenez-Roqueplo et al. came to the same conclusion
in 2003 [158]. Since then it could be demonstrated that
up to 30% of all patients with apparently sporadic HNPs
suffer from mutations in the genes SDHB, SDHC and
SDHD[9],[10],[142],[184],[194],[196].Themolecular
genetic screening of all HNP patients is therefore re-
garded as international standard by the majority of au-
thors.
On the other hand, screening for intragenetic mutations
as well as large deletions in all three genes costs approx-
imately 2700 US$ per patient [10]. In many cases, those
expensesarenotpaidforbyhealthinsurancecompanies.
Therefore, an algorithm for a cost effective screening
would be very helpful. Neumann et al. screened 598 pa-
tientswithapparentlysporadicHNPsformutationsofthe
genes SDHB, SDHC and SDHD [10]. All patients were
screenedformutationsinallthreegenes.Mutationswere
detected in 183 subjects (30.6%). There were 94 SDHD,
63 SDHB and 26 SDHC gene mutations, respectively. No
patient presented with more than one mutation. In the
next step, Neumann et al. looked for clinical predictors
that were associated with a high probability of an SDHx
mutation. A total of six first step predictors could be
identified: positive family history, previous pheochromo-
cytomas, multiple HNPs, manifestation of first tumor be-
fore age 40, male gender as well as malignant HNPs.
Based on those first step predictors, Neumann and
coworkers developed an algorithm (Figure 10). Using the
approachoftestingonlypatientswithfirststeppredictors
would have resulted in a cost reduction of approximately
60% in this group of 598 patients. On the other hand, a
total of 15 patients with SDHx mutations would not have
been detected [10].
Therefore, we recommend molecular genetic screening
of all HNP patients. In order to do this testing in a cost
effectivewaywithouthavingtheriskofmissingamutation
werecommendastepbystepapproach.Clinicalparamet-
ers will help to decide which gene should be tested first.
Only if this test is negative, the second gene would be
testet and so on.
We recommend the following approach for patients with
HNPs:
• multiple HNPs:
1) SDHD 2) SDHB 3) SDHC
• solitary HNP, positive family history:
1) SDHD 2) SDHB 3) SDHC
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1) SDHD 2) SDHB 3) SDHC
• solitary HNP, negative family history:
1) SDHB 2) SDHD 3) SDHC
• malignant HNP(s):
1) SDHB 2) SDHD 3) SDHC
This approach should be modified under certain circum-
stances. If family pedigree confirms a disease transmis-
sion from mother to child, showing lack of the parent-of-
origin effect seen in SDHD mutations, the SDHB gene
should be tested first, followed by the SDHC gene if ne-
cessary [10].
A routine screening of HNP patients for mutations of the
genes SDHAF2 (PGL 2), VHL (VHL syndrome) und RET
(MEN2) is not necessary.
PGL 2 has only been described in two families yet [160],
[161]. A screening for SDHAF2 gene mutations would
only be useful in an patient with hereditary HNPs in the
absence of an SDHB, SDHC and SDHD gene mutation.
HNPs are a part of the VHL tumor syndrome. Neverthe-
less,theyareextremelyuncommoncomparedtoheman-
gioblastomas, retinal angiomas, renal cysts, renal cell
cancer, pancreatic cysts and pheochromocytomas [174].
Before developing a HNP, patients with VHL syndrome
have usually developed one or multiple of the other neo-
plasms mentioned [169].
HNPsareexceedinglyrareinMEN2withonlythreesingle
cases published in the literature [20], [169], [170].
InpheochromocytomapatientswithoutHNPs,thepossib-
ility of an RET or VHL mutation have to be kept in mind
though.Inpatientswithsolitaryextraadrenalpheochromo-
cytomas Erlic et al. recommend a screening in the order
SDHB, VHL, SDHD and RET [193]. Whenever there is an
adrenal pheochromocytoma or in cases with multiple
pheochromocytomas the order of choice would be: VHL,
RET, SDHB and SDHD [169].
A thorough genetic counselling in combination with mo-
lecular genetic screening is essential. Patients and their
families have to be familiar of the clinical features of the
different hereditary HNP and pheochromocytoma syn-
dromes. Of special interest is the trait of inheritance and
here especially the parent-of-origin effect in PGL 1 and
PGL 2.
2.7.10 Follow-up for PGL patients
The life-time risk for patients with SDHB and SDHD
mutations to develop HNPs and/or pheochromocytomas
isveryhigh.WhereastumorpenetranceinSDHBmutation
carriers seems to be slightly lower, one has to consider
the high risk of PGL 4 patients for the development of
malignant paraganglial tumors and malignant renal cell
tumors [9], [10], [137], [142], [185], [195].
Those aspects have to be taken into consideration when
itcomestofollow-upofPGLpatients.Allmutationcarriers
should undergo a clinical and radiologic screening after
the molecular genetic diagnosis has been established.
The only exception is children of female SDHD mutation
carriers. In addition to a thorough physical examination
thefollowingproceduresshouldbeconsideredastandard
program:
• MRI with contrast medium of the head and neck, the
thorax and the abdomen
• Catecholamines or metanephrines in plasma or 24h
urine
Additional procedures such as an 18F-DOPA-PET may be
of great benefit in selected cases.
Inouropinion,patientswithSDHCmutationsshouldonly
undergoMRIofthethoraxandabdomenonce.Thereafter,
MRI follow up of the head and neck region together with
a physical examination should be sufficient, since PGL 3
harbours only a very low risk for the development of
pheochromocytomas.
SDHD patients who have already developed a
paraganglial tumor should undergo the whole standard
programonceayear.ForSDHDpatientswithoutanysigns
of tumor, stretching of intervals to three years seems to
be justified.
Duetothehighriskformalignanttumors,wesuggestthe
standard examination in SDHB patients once a year.
Whenever malignancy is expected, the 18F-DOPA-PET
has been an excellent tool in our hands.
SDHC patients with paraganglial tumors should undergo
yearly MRI of the head and neck as well as a thorough
physical examination. In SDHC patients who have not
developed any tumor yet, an MRI of the head and neck
together with a physical exam every three to five years
should be sufficient.
ThepercentageofSDHBandSDHDpatientswhodevelop
a tumor during the first two decades of life is rather high.
In the study by Burnichon et al., 21 out of 242 (8.7%)
SDHB and SDHD mutation carriers developed a tumor
before age 18 [197]. The authors therefore suggest to
start examinations in SDHB and SDHD patients at age 6.
Whenever a paraganglial tumor is detected in a PGL pa-
tientanindividualtherapyregimenshouldbedeveloped.
WhenitcomestoHNPs,ourgeneraltherapysuggestions
also apply to PGL patients. Pheochromocytomas of the
thoraxshouldbecompletelyresectedwheneverpossible.
Thesameistrueforadrenalandextraadrenalabdominal
pheochromocytomas. In recent years, a cortical sparing
laparoscopicpartialadrenalectomyhasbecomethegold
standard of surgery [206], [207], [208]. Neumann and
coworkers could demonstrate that even in cases of bilat-
eral adrenal tumors enough tissue can be left in place to
avoid the need for post-operative hormone therapy. The
risk for local recurrences has been shown to be very low
for this approach [206], [207].
3. Conclusion
Headandneckparagangliomas(HNPs)arerare,neuroen-
docrine neoplasms with a strong vascularisation. They
are most commonly found as carotid body tumors. Jugu-
lotympanicandespeciallyvagalparagangliomasareless
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domen are referred to as pheochromocytomas.
Post-operativedeficitsofthelowercranialnervesarethe
main risk of morbidity after surgical resection. Neverthe-
less, we recommend surgery as the therapy of choice for
the majority of all HNPs since complete tumor resection
representstheonlycurativetreatmentoption.Depending
on tumor size, number and localisation, the patients age
and general status and pretherapeutic cranial nerve
status other treatment options always have to be taken
into account. Those alternative options include conven-
tionalradiotherapy,stereotacticradiosurgeryanda“wait
and scan” policy.
ShamblinIIICBTsaswellasFischCandFischDjugulotym-
panicparagangliomasshouldalwaysundergopre-operat-
ive embolisation whenever a resection is planned. Fisch
Ajugulotympanicparagangliomasmustnotbeembolised.
In all other cases, the need for embolisation should be
individually decided.
Both HNPs and pheochromocytomas may occur as
sporadic as well as hereditary entities. Up to 30% of ap-
parently sporadic HNPs are associated with different tu-
morsyndroms.Approximately90%ofallhereditaryHNPs
are related to the paraganglioma syndromes (PGL) 1, 3
and 4. PGL 1 is associated with mutations in the gene
encoding succinate dehydrogenase subunit D (SDHD),
whereas PGL 3 ist due to SDHC and PGL 4 to SDHB gene
mutations. Trait of transmission is generally autosomal
dominantforallPGL.InPGL1thereisasocalled“parent-
of-origin-dependant-inheritance”. This means that muta-
tioncarriersonlysufferanincreasedriskfortumordevel-
opmentifthemutationhasbeentransmittedthroughthe
paternal line.
PatientswithPGL1,3and4developparaganglialtumors
atasignificantlyyoungeragewhencomparedtopatients
with sporadic HNPs and pheochromocytomas. SDHC pa-
tients develop benign, single HNPs in the great majority
of cases. SDHD mutation carriers frequently suffer from
multiple HNPs, whereas SDHB patients do have a signi-
ficantly increased risk for the development of malignant
paraganglialtumors.Malignantrenalcelltumorsarealso
detected in SDHB patients on a regular basis.
WerecommendamoleculargeneticscreeningofallHNP
patients for mutations of the genes SDHB, SDHC and
SDHD. The order of testing is performed according to in-
dividual clinical features. Whenever a mutation is detec-
ted, the affected patient should undergo a thorough
clinicalexamination,anMRIwithcontrastmediumofthe
head and neck, the thorax and the abdomen as well as
catecholaminesormetanephrinesinplasmaor24hurine.
The identification of patients with PGL will, in addition
with follow up examinations, lead to early detection of
HNPs and pheochromocytomas in the future. In turn,
carriersidentifiedearlyinthecourseoftheirdiseasecan
be brought to surgical attention before their disease be-
comes extensive and potentially life-threatening.
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